El interés en corto de Boston Scientific da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Boston Scientific. Los datos de interés en corto se actualizan cada dos semanas.

Boston Scientific (NYSE:BSX) Bolsa, Informe de interés en corto

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BBIO

ISRG

ITCI

Cuatro acciones del sector salud están mostrando señales de sobrecompra según el RSI. ¿Cómo afectará esto a su rendimiento?

4 acciones de salud sobrecompradas que podrían preocupar a los traders

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States Dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">BridgeBio Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>)</h3>
<ul>
<li>On Nov. 22, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.. The company's stock surged around 28% over the past month and has a <a href="https://www.benzinga.com/quote/BBIO">52-week high of $41.04</a>.</li>
<li>RSI Value: 71.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>BBIO Price Action: Shares of BridgeBio Pharma fell 0.9% to close at $33.79 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>)</h3>
<ul>
<li>On Jan. 15, Intuitive Surgical reported strong preliminary fourth-quarter results. "We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year. We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes," said Gary Guthart, CEO of Intuitive Surgical. The company's stock gained around 9% over the past five days and <a href="https://www.benzinga.com/quote/ISRG">has a 52-week high</a> of $597.68.</li>
<li>RSI Value: 72.6</li>
<li>ISRG Price Action: Shares of Intuitive Surgical gained 1.5% to close at $592.64 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Boston Scientific Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</h3>
<ul>
<li>On Jan. 8, Boston Scientific agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and peripheral artery disease. The company's stock gained around 11% over the past month and has a <a href="https://www.benzinga.com/quote/BSX">52-week high</a> of $99.14.</li>
<li>RSI Value: 75.3</li>
<li>BSX Price Action: Shares of Boston Scientific gained 0.5% to close at $98.66 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Intra-Cellular Therapies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)</h3>
<ul>
<li>On Jan. 13, Johnson &amp; Johnson entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash in a deal that values the company at approximately $14.6 billion. The company's stock jumped around 51% over the past month and has a 52-week high is $128.00.</li>
<li>RSI Value: 85.6</li>
<li>ITCI Price Action: Shares of Intra-Cellular Therapies fell 0.05% to close at $126.20 on Friday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Top 4 Health Care Stocks You May Want To Dump In Q1

Boston Scientific To Present Data Supporting Use Of FARAPULSE Pulsed Field Ablation System And WATCHMAN FLX Left Atrial Appendage Closure Device

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 10 years by 9.7% on an annualized basis producing an average annual return of 21.06%. Currently, Boston Scientific has a market capitalization of $142.86 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 10 years ago, it would be worth $6,761.34 today based on a price of $97.01 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736982008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Analyst Ratings

iShares Dow Jones US Financial Sector Index Fund

CNBC Halftime Report Final Trades: Apollo Global Management, UnitedHealth Group, iShares U.S. Financial ETF, Boston Scientific

On Wednesday, Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42869851/boston-scientific-announces-agreement-to-acquire-bolt-medical-inc" rel="noreferrer noopener">peripheral artery disease</a>.
Cholesterol deposits often create narrowed arteries and may also have a buildup of calcium that can increase the complexity of potential treatments. Lithotripsy is a procedure in which a physician breaks up hardened masses such as calcium to help restore blood flow.
The Bolt IVL system is designed to use lithotripsy to fracture calcium by creating acoustic pressure waves inside a balloon catheter.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42624916/boston-scientific-updates-instructions-for-cryoablation-balloons-after-reports-of-severe-injuries" rel="noreferrer noopener">Boston Scientific Updates Instructions for Cryoablation Balloons After Reports Of Severe Injuries</a>
The system also includes visible, directional emitters for consistent energy delivery in treating the calcified lesions.
Boston Scientific initially developed the concept for the Bolt IVL system, which helped establish Bolt Medical in 2019.
As a strategic investor in Bolt Medical, Boston Scientific has an equity stake of approximately 26%.
As a result, the transaction consists of an upfront payment of approximately&nbsp;$443 million&nbsp;for the 74% stake not yet owned and up to&nbsp;$221 million&nbsp;upon achievement of certain regulatory milestones.
On a 100% basis, before consideration of Boston Scientific&#8217;s current equity ownership in Bolt Medical, debt, and other closing adjustments, the transaction price consists of&nbsp;$600 million&nbsp;upfront and up to&nbsp;$300 million&nbsp;upon achievement of certain regulatory milestones.
Bolt Medical recently announced the completion and results of the RESTORE ATK and RESTORE BTK pivotal clinical trials investigating the Bolt IVL Above the Knee and Below the Knee systems for peripheral artery disease in patients with moderate to severely calcified lesions.
In&nbsp;December 2024, Bolt Medical received FDA approval to commence the global FRACTURE IDE clinical trial in the U.S., which is investigating the use of the Bolt IVL&#x2122; Coronary System for the treatment of coronary arterial disease with severely calcified lesions.
The deal is expected to be completed in the first half of 2025.
On an adjusted basis, the company expects the transaction to be slightly dilutive to adjusted EPS in 2025 and to offset via internal cost efficiencies and trade-offs. 
On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges, except for a one-time gain to be recognized at closing associated with the company&#8217;s previously held equity interest in Bolt Medical. 
Price Action: BSX stock is up 4.91% at $96.51 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42877913/jasper-therapeutics-skin-disorder-candidate-data-fails-to-cheer-investors" target="_blank" rel="noreferrer noopener">Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Movers

General

Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal

U.S. stocks were lower, with the Dow Jones index falling over 150 points on Wednesday.
Shares of AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) rose sharply during Tuesday's session after posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/25/01/42862022/aar-shares-climb-on-better-than-expected-q2-results-details">second-quarter results.</a>
The company reported quarterly earnings of 90 cents per share, which beat the analyst consensus estimate of 84 cents. Quarterly revenue came in at $686.1 million, which beat the analyst consensus estimate of $654.18 million.
AAR shares jumped 9.6% to $67.67 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares jumped 249% to $5.77 after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.</li>
<li>Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) gained 64% to $12.97 after the company announced it&#8217;s presenting initial Phase 1 data from its two dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) surged 25% to $11.74 after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 17% to $3.5900 after the company announced a strategic collaboration with AMD.</li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) surged 11.5% to $70.44 after Meta announced a test in Germany, France and the US that will allow buyers to browse eBay listings directly on Facebook Marketplace.</li>
<li>Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) gained 10.2% to $29.87 as the company agreed to sell SGK Brand Solutions.</li>
<li>Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose 8.6% to $5.72 after the company announced it secured CFIUS clearance regarding Rio Tinto&#8217;s proposed acquisition.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) gained 7.1% to $111.00 as the company posted better-than-expected results for its second quarter. The company said it set a quarterly record for total dozens sold and specialty dozens sold. It also announced a cash dividend of approximately $1.49 per share.</li>
<li>ADTRAN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) rose 6.3% to $10.25.</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) gained 4.6% to $96.24 after the company announced it entered into a definitive deal to acquire Bold Medical.</li>
<li>UniFirst Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) gained 3.7% to $212.25 following upbeat quarterly earnings.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower</a></li>
</ul>

Intraday Update

ABSI

ADTN

ALTM

ANGO

CALM

EBAY

MATW

SANA

AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday

WIIM

Boston Scientific shares are trading higher after the company announced it entered into a definitive deal to acquire Bold Medical.

As a strategic investor in Bolt Medical, Boston Scientific has an equity stake of approximately 26 percent. As a result, the transaction consists of an upfront payment of approximately&nbsp;$443 million&nbsp;for the 74 percent stake not yet owned and up to&nbsp;$221 million&nbsp;upon achievement of certain regulatory milestones.
Boston Scientific anticipates the transaction to be completed in the first half of 2025, subject to customary closing conditions. On an adjusted basis, the company expects the transaction to be slightly dilutive to adjusted earnings per share (EPS) in 2025, and to offset via internal cost efficiencies and trade-offs.&nbsp;

Boston Scientific Enters Definitive Deal To Acquire Bolt Medical; Transaction Consists Of  Upfront Payment Of $443M For The 74% Stake Not Yet Owned

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/25/01/42755273/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-december-2024-where-do-tesla-nvidia-quantum-computing-stock-rank" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In December 2024 — Where Do Tesla, Nvidia, Quantum Computing Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week ending Jan. 3:
Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>): The ride-share company saw strong interest over the last week and to kick off the new year with Goldman Sachs<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42777529/goldman-sachs-adds-3-stocks-to-conviction-list-flags-5-market-trends-to-monitor-in-2025"> adding the stock</a> to its "Conviction List." Analyst Erik Sheridan sees strong compound annual growth and adjusted EBITDA coming for Uber over the next two years and has a price target of $96 on the stock. Uber may also be seeing strong interest in 2025 with The Information predicting that rival Lyft could see buyout interest.
Uber stock was up around 6% over the last five trading days as seen on the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"> Benzinga Pro chart </a>below and shares are up 12% over the last year.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162855/Screenshot-284.png" alt="" class="wp-image-717805" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162855/Screenshot-284.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162855/Screenshot-284-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162855/Screenshot-284-768x384.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Read Also: <a href="https://www.benzinga.com/general/travel/24/12/42702929/ubers-death-cross-chart-looks-terrible-yet-jim-cramer-sees-opportunity">Uber&#8217;s Death Cross: Chart Looks &#8216;Terrible,&#8217; Yet Jim Cramer Sees Opportunity</a>
Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): The medical devices company makes a <a href="https://www.benzinga.com/exclusives/24/03/37894121/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">return to the </a>Stock Whisper Index after appearing in March. Shares trade near 52-week highs and analysts continue to raise their <a href="https://www.benzinga.com/quote/BSX/analyst-ratings">price targets.</a> Evercore raised the price target from $95 to $100 and BITG raised the price target from $97 to $101. The company said recently that it will present at the JPMorgan Healthcare Conference on Jan. 13, which could provide more updates and catalysts for 2025.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162929/Screenshot-285.png" alt="" class="wp-image-717809" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162929/Screenshot-285.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162929/Screenshot-285-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162929/Screenshot-285-768x384.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>): The construction and facilities services company saw strong interest from investors over the week with limited new news. The company could be on the radar of investors with construction and business spending expected to be growth areas in 2025. EMCOR could also be seeing increased interest with the recent announcement that Amy Dahl was <a href="https://www.businesswire.com/news/home/20241219066760/en/Amy-E.-Dahl-Elected-to-the-EMCOR-Group-Inc.-Board-of-Directors">named </a>to the company's Board of Directors. Dahl serves as vice president, International Business &amp; Strategy for The Toro Company and her expertise in outdoor turf and landscape maintenance could help EMCOR in new business segments.
EMCOR stock is up over 120% in the last year and investors continue to look at the name for more upside ahead.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162943/Screenshot-286.png" alt="" class="wp-image-717810" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162943/Screenshot-286.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162943/Screenshot-286-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162943/Screenshot-286-768x391.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>): The Latin American e-commerce company saw strong interest from readers over the last week and could be a theme ahead as investors look for exposure to countries that could benefit under a new White House administration or are seeing growth from populations and income levels. The company has operations across several segments including e-commerce, shipping, logistics, advertising and fintech and operates in multiple countries. The stock recently appeared on the Stock Whisper Index with strong interest in the name <a href="https://www.benzinga.com/trading-ideas/24/12/42628286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-including-qubt-qbts">in December</a>. The company's third-quarter revenue beat analyst estimates for an eighth straight quarter.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163001/Screenshot-287.png" alt="" class="wp-image-717811" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163001/Screenshot-287.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163001/Screenshot-287-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163001/Screenshot-287-768x389.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>): The financial services stock saw strong interest among readers over the last week and continues to be a popular stock among retail investors. Keefe, Bruyette and Woods <a href="https://www.benzinga.com/quote/SOFI/analyst-ratings">downgraded </a>shares from market Perform to Underperform and raised the price target from $7 to $8. The analyst <a href="https://www.benzinga.com/general/market-summary/25/01/42762341/sofi-tech-downgraded-over-valuation-concerns-stock-priced-three-times-its-peers">cited concerns</a> on valuation and a lack of long-term earnings potential. Lower interest rates could be providing optimism for investors looking at the stock. Another reason the stock might be on investors' radar is the company's student loan segment. With Donald Trump returning to the White House, <a href="https://www.benzinga.com/24/12/42673338/biden-dumps-student-loan-forgiveness-plans">student loan forgiveness programs</a> under President Joe Biden could be coming to an end.
SoFi shares were down 10% over the last five trading days, but are up over 70% in the last year.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163018/Screenshot-288.png" alt="" class="wp-image-717812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163018/Screenshot-288.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163018/Screenshot-288-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163018/Screenshot-288-768x386.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42366750/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">December 6</a></li>
<li><a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">December 13</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42628286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-including-qubt-qbts" target="_blank" rel="noreferrer noopener">December 20</a></li>
<li><a href="https://www.benzinga.com/media/24/12/42709387/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">December 27</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42638753/quantum-computing-the-new-ai-a-look-at-the-rapidly-expanding-market-and-top-stocks-for-2025" target="_blank" rel="noreferrer noopener">Quantum Computing: The New AI? A Look at the Rapidly Expanding Market and Top Stocks For 2025</a></li>
</ul>

Exclusives

MELI

SOFI

UBER

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 10 years by 9.12% on an annualized basis producing an average annual return of 20.37%. Currently, Boston Scientific has a market capitalization of $131.90 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 10 years ago, it would be worth $6,537.96 today based on a price of $89.57 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735836310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Boston Scientific 10 Years Ago Would Be Worth Today

On Wednesday, Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) revised the usage guidelines for its Polarx and Polarx FIT cryoablation balloon catheters following reports of serious injuries, including seven cases of esophageal <a target="_blank" href="https://www.benzinga.com/quote/BSX" rel="noreferrer noopener">damage and four deaths</a>.
Boston Scientific is updating use instructions for POLARx Cryoablation Balloon Catheters due to a higher than anticipated number of reports of esophageal injury, specifically atrio-esophageal fistula, after catheter ablation procedures for atrial fibrillation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42043081/why-is-medical-device-giant-boston-scientific-stock-trading-higher-on-monday" rel="noreferrer noopener">Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?</a>
The <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/catheter-correction-boston-scientific-updates-use-instructions-polarx-and-polarx-fit-cryoablation?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">updates</a> emphasize the risk of atrio-esophageal fistula and practices that may minimize risk, based on the observation that location, frequency, and intensity of cryoablation applications may be contributing factors to this complication.
The use of affected product may cause serious adverse health consequences, including atrio-esophageal fistula leading to air bubbles blocking blood vessels in the brain (cerebral air embolism), stomach and intestinal (gastrointestinal) bleeding, a system-wide infection (septic shock), and death.
The devices, approved in the U.S. in August 2023, treat recurrent atrial fibrillation (an irregular heartbeat). Polarx has been in use in <a target="_blank" href="https://www.benzinga.com/pressreleases/23/08/n33642542/boston-scientific-receives-fda-approval-for-the-polarx-cryoablation-system" rel="noreferrer noopener">Europe since 2020</a>.
Updated instructions now emphasize:
<ul>
<li>Monitoring the catheter&#8217;s position relative to the esophagus.</li>
<li>Avoiding cryotherapy directly over the esophagus.</li>
<li>Using established practices for balloon positioning, esophageal monitoring, and nerve safety.</li>
</ul>
Earlier this week, Boston Scientific announced a&nbsp;<a target="_blank" href="https://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety" rel="noreferrer noopener">recall</a> for a subset of Accolade pacemaker devices with an increased risk of permanently entering Safety Mode. This mode has limited functionality and has been associated with the pacemaker being unable to properly regulate the heart&#8217;s rhythm and rate in some patients.
A device that enters Safety Mode should be replaced. The increased risk of permanently entering Safety Mode in this subset of Accolade pacemaker devices is due to the battery underpowering the system because of a manufacturing issue.&nbsp;
Price Action: BSX stock is up 0.96% at $89.52 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42618042/why-penny-stock-foresight-autonomous-stock-is-gaining-today" target="_blank" rel="noreferrer noopener">Why Is Penny Stock Foresight Autonomous Stock Gaining Today?</a></li>
</ul>
Photo via Shutterstock.

Equities

Boston Scientific Updates Instructions for Cryoablation Balloons After Reports Of Severe Injuries

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 5.0% on an annualized basis producing an average annual return of 16.65%. Currently, Boston Scientific has a market capitalization of $128.85 billion. 
Buying $100 In BSX: If an investor had bought $100 of BSX stock 15 years ago, it would be worth $1,007.02 today based on a price of $87.50 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734710410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $100 to $110.

Price Target

Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $110

JP Morgan analyst Robbie Marcus maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $100 to $110.

JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $110

Date Issued: December 16, 2024
The U.S. Food and Drug Administration (FDA) is alerting patients, caregivers, and health care providers about the potential need for early device replacement of Boston Scientific Corporation (Boston Scientific) Accolade pacemaker devices, which includes the Accolade, Proponent, Essentio, and Altrua 2 Standard Life (SL) and Extended Life (EL) pacemakers, and the Visionist and Valitude cardiac resynchronization therapy pacemakers.
Boston Scientific announced a <a href="https://www.bostonscientific.com/content/dam/bostonscientific/quality/documents/Recent%20Product%20Advisories/2024_Dec_BSC_ACCOLADE_HighImpedance_PhysLtr_FINAL7_US.pdf">recall</a> for a subset of Accolade pacemaker devices with an increased risk to permanently enter Safety Mode, which has limited functionality and has been associated with the pacemaker being unable to properly regulate the heart's rhythm and rate in some patients. A device that enters Safety Mode should be replaced. The increased risk of permanently entering Safety Mode in this subset of Accolade pacemaker devices is due to the battery underpowering the system because of a manufacturing issue. &nbsp;
While the recall by Boston Scientific identifies a subset of Accolade pacemaker devices with increased risk of entering Safety Mode, the FDA is working with the manufacturer to evaluate the potential risk of this issue in all Accolade pacemaker devices and identify additional mitigation strategies as needed.&nbsp;
The FDA is issuing this communication to raise awareness of the manufacturer's recall notice, the FDA's ongoing evaluation with the manufacturer of the issue, and the FDA's current recommendations.
<h2>Recommendations for Patients and Caregivers</h2>
<ul>
<li>Continue to work with your health care provider to monitor your Accolade pacemaker device, either remotely or during your existing in-office follow-up schedule.&nbsp;
<ul>
<li>Discuss with your health care provider if you are a candidate for remote monitoring. Remote monitoring enables your provider to receive regular updates, including a Safety Mode alert, from your device.&nbsp;</li>
<li>If not a candidate for remote monitoring, discuss an in-office monitoring schedule with your health care provider to help ensure that your device is functioning properly.&nbsp;</li>
<li>If monitoring indicates that your device entered Safety Mode, discuss a plan with your health care provider for surgery to replace the pacemaker.&nbsp;</li>
</ul>
</li>
<li>Discuss your current pacing needs and potential risk of your device entering Safety Mode with your health care provider.
<ul>
<li>If you are determined to be at high risk of harm &nbsp;if your device entered Safety Mode based on your pacing needs, your health care provider may contact you about replacement of your device.</li>
</ul>
</li>
<li>Consult with your health care provider if you have new or worsening symptoms such as lightheadedness or loss of consciousness, or questions about your device potentially entering Safety Mode.&nbsp;</li>
<li><a href="http://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety#reporting">Report any problems</a> with your Accolade pacemaker device to the FDA.</li>
</ul>
<h2>Recommendations for Health Care Providers</h2>
<ul>
<li>Review the <a href="https://www.bostonscientific.com/content/dam/bostonscientific/quality/documents/Recent%20Product%20Advisories/2024_Dec_BSC_ACCOLADE_HighImpedance_PhysLtr_FINAL7_US.pdf">recall notice</a> from Boston Scientific for a subset of Accolade pacemaker devices with an increased risk to permanently enter Safety Mode due to the battery underpowering the system because of a manufacturing issue with the battery cathode. The recall notice includes the following important information:
<ul>
<li>Description of the battery problem and clinical impact of Safety Mode,</li>
<li>Recommended actions for individual patient evaluation, device replacement, and follow-up intervals, and</li>
<li>Model numbers and Unique Device Identifier (UDI) information.&nbsp;</li>
</ul>
</li>
<li>Be aware that the FDA is working with the manufacturer to evaluate the potential risk of this issue in all Accolade pacemaker devices.
<ul>
<li>Consider the potential need for early device replacement and a patient's specific reliance on their pacemaker when making treatment recommendations.</li>
<li>Discuss the benefit and risks of all available treatment options with your patients.&nbsp;</li>
<li>Remain alert for further updates and recommendations from the FDA and the manufacturer.</li>
<li>While the FDA's evaluation is ongoing, health care providers should:
<ul>
<li>Monitor patients with Accolade pacemaker devices through remote or in-office visits for red box alerts indicating that a patient's device is in Safety Mode, or symptoms indicating device performance issues, such as lightheadedness or loss of consciousness. General prophylactic device replacement is not recommended.&nbsp;</li>
<li>If monitoring indicates that the device has entered Safety Mode, schedule surgery for a replacement pacemaker. Timely replacement is recommended to avoid risks associated with time spent in Safety Mode.</li>
</ul>
</li>
</ul>
</li>
<li><a href="http://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety#reporting">Report any problems</a> your patients experience with Accolade pacemaker devices to the FDA.</li>
</ul>
<h2>Device Description</h2>
The Accolade devices are a family of pacemakers and cardiac resynchronization therapy pacemakers that are implanted to treat abnormal heartbeat (arrhythmia) and moderate to severe heart failure.
<h2>Potential Need for Early Device Replacement of Accolade Pacemaker Devices</h2>
The FDA is aware of a manufacturing issue with the cathode of some Accolade pacemaker device batteries that may lead to underpowering the device system and may cause the pacemakers to permanently enter Safety Mode, which requires pacemaker replacement.
Pacemakers that enter Safety Mode require replacement because Safety Mode offers limited functioning of the pacemaker and has been associated with the pacemaker being unable to properly regulate the heart's rhythm and rate in some patients. Safety Mode can only be identified through office visits or through remote monitoring using the Boston Scientific Latitude Communicator system.
The manufacturer plans to implement updated manufacturing work instructions for the process used to make the cathodes for Accolade product batteries. In addition, the manufacturer is developing a software update to detect battery health in all Accolade pacemaker devices.
<h2>FDA Actions</h2>
The FDA will continue working with Boston Scientific to help ensure that patients, caregivers, and providers are aware of the issue, evaluate information to better understand the issue, and to identify additional mitigation strategies as needed. &nbsp; &nbsp;
The FDA will continue to monitor information about device performance including medical device reports.
The FDA will keep the public informed as new information becomes available.

FDA Alerting About Potential Need For Early Device Replacement Of Boston Scientific Accolade Pacemaker Devices; Boston Scientific Announced Recall For Subset Of Accolade Pacemaker Devices With Increased Risk To Permanently Enter Safety Mode

TD Cowen analyst Joshua Jennings maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $100 to $110.

TD Cowen Maintains Buy on Boston Scientific, Raises Price Target to $110

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $98 to $107.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $107

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) underwent analysis by 18 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $98.06, a high estimate of $110.00, and a low estimate of $86.00. Surpassing the previous average price target of $90.44, the current average has increased by 8.43%.
<img src="https://www.benzinga.com/files/images/story/2024/1733936428_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Boston Scientific among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$98.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Bob Hopkins</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$93.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Boston Scientific's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Boston Scientific's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>Get to Know Boston Scientific Better</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Boston Scientific's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 19.34% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Boston Scientific's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Boston Scientific's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Boston Scientific's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.25%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.54, Boston Scientific adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Boston Scientific Analyst Ratings

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $98 to $100.

Wells Fargo Maintains Overweight on Boston Scientific, Raises Price Target to $100

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $98 to $101.

Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $101

The company states: "Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System&#x2A; and the WATCHMAN FLX ...

Boston Scientific announces data supporting use of FARAPULSE PFA system

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Marie Thibault ...

Boston Scientific's Promising Trial Outcomes and Market Expansion Drive Buy Rating

Piper Sandler Keeps Their Buy Rating on Boston Scientific (BSX)

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target o...

Boston Scientific (BSX) Gets a Buy from TD Cowen

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The company'...

Truist Financial Gives a Buy Rating to Boston Scientific (BSX)

Morgan Stanley analyst Patrick Wood maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of $100.00. P...

Positive ADVANTAGE AF Trial Outcomes Reinforce Buy Rating for Boston Scientific

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

Beckton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Becton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Barclays raised the firm's price target on Boston Scientific (BSX) to $111 from $86 and keeps an Overweight rating on the shares. The firm says its...

Boston Scientific price target raised to $111 from $86 at Barclays

ABBV

ABCL

CGON

GILD

ILMN

REGN

RHHBY

RHHVF

RLAY

TCHBF

Press Releases

Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

"Power Nickel (TSX.V: PNPN) (OTCQB: PNPNF) Announces Dividend – MIGI, PRFX, PBM, CSDX Stocks Trending Now!"

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Entertainment

Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace

Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results

Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.

Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type 1 Diabetes, CS Diagnostics (OTCQB: CSDX) Cancer Therapy – CURR, TPET, PRSO, PNPN.V, EONR – Plus More Stocks Under $2 Inside See Now!

Comments

Boston Scientific

Interés en corto

Boston Scientific (NYSE:BSX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL